QUIET-1: AUT00063 (Kv3 modulator) Phase 2a — terminated for futility

Record details

Authors: Hall DA, Ray J, Watson J, et al.
Journal / source: Hearing Research (2019)
Design: Randomized placebo-controlled Phase 2a
Sample: 91
Primary endpoint: TFI
Randomized: Yes · Sham/placebo-controlled: Yes · Independent of the manufacturer: No

What this research found

Terminated early for futility; TFI change ~1.6 points despite therapeutic-range drug exposure.

Limitations and conflicts of interest

—

Funding / conflicts: Sponsor-run (Autifony).

Corrections to this record

2026-09-04: Citation-hygiene fix: year: 2018 → 2019; pmid: None → '30939361'; doi: None → '10.1016/j.heares.2019.03.018'; n: '—' → '91'

Primary sources

Used as evidence for

Off-label oral drugs (antidepressants, benzodiazepines, gabapentin, betahistine)

This is an original summary from the Tinnitus Evidence verified database, checked against the primary source — not a reproduction of the publisher's abstract.